期刊
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION
卷 16, 期 1, 页码 16-20出版社
SAGE PUBLICATIONS LTD
DOI: 10.1097/HJR.0b013e32830aba5c
关键词
aging; cardiovascular diseases; risk assessment; serum gamma glutamyltransferase
资金
- National Heart, Lung, and Blood Institute
- National Institutes of Health, Bethesda, Maryland
- Mayo Chair Endowment [RO1-HI-23727]
- School of Public Health
- University of Minnesota (DJ)
- The Netherlands Heart Foundation [2005R013, BB]
Background Although serum gamma-glutamyltransferase (GGT) predicted cardiovascular diseases (CVD) in prospective studies and may be useful in risk assessment, prediction in older adults was weaker in several studies. Methods We performed a nested case-control study with 5-12-year follow-up in 137 CVD deaths and 249 controls (frequency-matched on age, sex, and examination year, age range 26-85 years). Results An age interaction of serum GGT and CVD mortality (P value for interaction=0.02) was observed. After adjusting for known CVD risk factors, compared with the lowest tertile, odds ratios (95% confidence intervals) in participants less than 70 years (half the participants) were: middle tertile: 2.17 (0.68-6.97), top tertile up to GGT less than 50 U/I: 3.54 (1.07-11.7), and GGT >= 50 U/I: 4.69 (1.16-18.9). In participants aged more than or equal to 70 years, GGT was not related to CVD. Well-known demographic and health behavior associations with serum GGT were observed only in controls among participants aged less than 70 years. Conclusion Our findings suggest that serum GGT within its normal range can predict CVD mortality in those aged less than 70 years, but may have limited usefulness for risk assessment in older adults. Eur J Cardiovasc Prev Rehabil 16:16-20 (C) 2009 The European Society of Cardiology
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据